| 李世强,万继峰,果海姣,刘文丽,白腾辉.补肝汤联合多巴丝肼片治疗帕金森病的临床效果[J].中国医药导报,2024,21(2):90-94 |
二维码（扫一下试试看！） |
| 补肝汤联合多巴丝肼片治疗帕金森病的临床效果 |
| Clinical effect of Bugan Decoction combined with Dopashydrazine Tablets on the treatment of Parkinson disease |
| 收稿日期：2023-06-06 |
| DOI：10.20047/j.issn1673-7210.2024.02.18 |
| 关键词: 补肝汤 多巴丝肼片 帕金森病 疗效 |
| Key Words: |
| 基金项目:国家重点研发计划(云计算和大数据专项)资助项目（2017YFB1002304）；北京中医药大学基本科研业务费项目（2021-JYB-XJSJJ-061） |
|
| 摘要点击次数: 293 |
| 全文下载次数: 285 |
| 摘要:目的 研究补肝汤联合多巴丝肼片对帕金森病患者的治疗效果。 方法 选取2018年1月至2022年5月北京中医药大学东直门医院脑病一科门诊及病房120例肝胃不和的帕金森病患者。依据随机数字表法将其分为西药组、中药组、联合组，各40例。西药组给予多巴丝肼片口服，中药组给予补肝汤口服，联合组同时服用多巴丝肼片和补肝汤，治疗8周。治疗前、治疗4周、治疗8周，比较三组39项帕金森病生活质量问卷（PDQ-39）评分、帕金森病综合评分量表（UPDRS）、白细胞介素-6（IL-6）和肿瘤坏死因子-α（TNF-α）；比较三组中医症候疗效；观察三组不良反应发生情况。 结果 整体比较：西药组与联合组及中药组与联合组PDQ-39、UPDRS评分组间、时间及交互作用比较，差异有统计学意义（P＜0.05）。组内比较：治疗4、8周，三组PDQ-39、UPDRS评分低于治疗前（P＜0.05）。组间比较：治疗4、8周，联合组PDQ-39评分低于西药组和中药组（P＜0.05）。治疗4周时，联合组UPDRS评分高于西药组和中药组（P＜0.05）；治疗8周时，联合组UPDRS评分低于西药组和中药组（P＜0.05）。整体比较：西药组与联合组及中药组与联合组IL-6、TNF-α水平组间、时间及交互作用比较，差异有统计学意义（P＜0.05）。组内比较：治疗4、8周，三组IL-6、TNF-α水平低于治疗前（P＜0.05）；组间比较：治疗4、8周，联合组IL-6、TNF-α水平低于西药组和中药组（P＜0.05）。联合组中医症候临床疗效优于西药组、中药组（P＜0.05）。中药组未发生不良反应，西药组与联合组不良反应总发生率比较，差异无统计学意义（P＞0.05）。 结论 补肝汤联合多巴丝肼片对帕金森病有良好的治疗效果，可作为临床治疗帕金森病的新的治疗思路。 |
| Abstract:Objective To study the therapeutic effect of Bugan Decoction combined with Dopashydrazine Tablets on Parkinson disease. Methods A total of 120 Parkinson disease patients with liver-stomach disharmony were selected from the outpatient and ward of the First Department of Encephalopathy, Dongzhimen Hospital Beijing University of Chinese Medicine from January 2018 to May 2022. They were divided into western medicine group, Chinese medicine group, and combination group, with 40 cases in each group. Western medicine group was treated with Dopashydrazine Tablets, while the Chinese medicine group was treated with Bugan Decoction, and the combination group was treated with Dopashydrazine Tablets combined and Bugan Decoction, the treatment lasted for eight weeks. The 39-item Parkinson disease quality of life questionnaire (PDQ-39), unified Parkinson disease rating scale (UPDRS), interleukin-6 (IL-6), and tumor necrosis factor-α(TNF-α) among three groups were compared before treatment, four weeks after treatment, and eight weeks after treatment; traditional Chinese medicine symptoms curative effect among three groups were compared; the incidence of adverse reactions among three groups were observed. Results Overall comparison: there were significant differences in PDQ-39 and UPDRS scores between groups, time, and interaction between western medicine group and combined group, Chinese medicine group and combination group (P＜0.05). Intra-group comparison: after four and eight weeks of treatment, PDQ-39 and UPDRS scores in three groups were lower than those before treatment (P＜0.05). Comparison between groups: after four and eight weeks of treatment, POQ-39 scores in combined groups were lower than those in western medicine group and Chinese medicine group(P＜0.05). After four weeks of treatment, UPDRS scores in combined group were higher than those in western medicine group and Chinese medicine group (P＜0.05); after eight weeks of treatment, UPDRS scores in combination group were lower than those in western medicine group and Chinese medicine group (P＜0.05). Overall comparison: there were significant differences in the levels of IL-6 and TNF-α between groups, time, and interaction between western medicine group and combined group, Chinese medicine group and combination group (P＜0.05). Intra-group comparison: after four and eight weeks of treatment, the levels of IL-6 and TNF-α in three groups were lower than those before treatment (P＜0.05); inter-group comparison: after four and eight weeks of treatment, the levels of IL-6 and TNF-α in combined group were lower than those in western medicine group and Chinese medicine group (P＜0.05). The clinical curative effect of combined group was better than that of western medicine group and Chinese medicine group (P＜0.05). No adverse reactions occurred in Chinese medicine group， there was no significant difference in the total incidence of adverse reactions between the western medicine group and combined group (P＞0.05). Conclusion Bugan Decoction combined with Dopashydrazine Tablets has a good therapeutic effect on Parkinson disease, and can be used as a new therapeutic idea to treat Parkinson disease. |
| 查看全文 HTML 查看/发表评论 下载PDF阅读器 |
|
|
|
